Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

By A. Kearns, S. Khosla, P. Kostenuik. Endocrine reviews, 2008

800 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “Indeed, OPG expression is often regulated in an opposite manner by factors that alter RANKL expression: upregulation of RANKL is associated with downregulation of OPG, or vice versa, altering the ratio of RANKL to OPG [24].”
Matrix-embedded cells control osteoclast formation (2011, background): “According to the prevailing paradigm, osteoblasts on the bone surface, or their progenitors in the marrow, supply the RANKL responsible for osteoclast generatio”
Estrogen and the Skeleton (2012, unknown): “Bone remodeling begins by the initiation of bone resorption by osteoclasts, and consistent with the critical role of osteocytes in this process, recent studies have demonstrated that they represent an important source of receptor activator of NFκB ligand (RANKL) in bone (12, 13), although it is like”